Research Funding Opportunities
We want to help kidney cancer researchers locate funding opportunities. We’ll update this page with grant opportunities as we learn about them.
Know of one we haven’t listed? Email us at email@example.com, or tweet at us, and we’ll get it posted!
KidneyCAN is dedicated to accelerating kidney cancer research.
Our advocacy for the DoD Kidney Cancer Research Program resulted in appropriations of $50 million in fiscal year 2023 for kidney cancer research, bring the 2017-2023 total to $235 million. In 2016, this number was $0.
The Kidney Cancer Research Summit brings translational researchers in kidney cancer together in an annual collaborative meeting.
Additionally, KidneyCAN’s “Rock the Cure” events have raised over $1,000,000 toward private research support.
KCRP FY23 FUNDING OPPORTUNITIES RELEASED
- Academy of Kidney Cancer Scholars – Early-Career Scholar Award
- Clinical Trial Award
- Concept Award
- Idea Development Award (New for FY23: Partnering Principal Investigator Option)
- Nurse-Initiated Research Award
- Postdoctoral and Clinical Fellowship Award
- Translational Research Partnership Award
ARPA-H supports high-impact biomedical research for equitable health solutions. Their model empowers program managers to tackle problems by working with a range of performers and approaches, and emphasizing measurement and evaluation for real-world impact.
The Advanced Research Projects Agency for Health (ARPA-H) seeks proposals for high-impact biomedical and health research to tackle society’s most challenging health problems, including cancer. The agency will fund groundbreaking, innovative research that can rapidly achieve better health outcomes across patient populations, communities, diseases, and health conditions.
Proposals must use novel approaches to enable revolutionary advances in science, technology, or systems. ARPA-H has identified four initial focus areas:
- Health Science Futures
- Scalable Solutions
- Proactive Health
- Resilient Systems
ARPA-H may consider submissions outside of these areas if they develop novel capabilities to improve health outcomes or prolong well-being. The agency will fund efforts across the spectrum of technology readiness, from foundational science to introducing new prototypes into the marketplace.
FUNDING OPPORTUNITY ANNOUNCEMENT
ARPA-H FREQUENTLY ASKED QUESTIONS
“ARPA-H will support concepts brought to life directly from Program Managers that have not only identified a key problem in health today, but are also passionate about a vision to bring forward revolutionary solutions to solve the problem, and do so in an equitable way.
“ARPA-H embraces a culture of open innovation and empowers its Program Managers to fearlessly pursue health breakthroughs that cannot readily be accomplished through traditional research or commercial activity. Program Managers at ARPA-H will serve an initial appointment of three years, and no more than six years total, to ensure a constant rotation of new ideas and diverse perspectives.”
Since 1993, the American Association for Cancer research has awarded more than $540 million in funds toward almost 1,000 different grants. In 2021, the AACR awarded over $7 million.
The ACCR supports grantees from the United States and abroad, at every career stage. These grants accelerate cancer research.
We’d love to see more RCC applicants for these prestigious grant opportunities.
KidneyCAN hosted the 5th Annual Kidney Cancer Research Summit on July 13–14, 2023, live in Boston, Massachusetts at the InterContinental Boston and virtually via Zoom webinar.
KCRS is an annual meeting of clinicians, researchers, research advocates, scientists, medical oncologists, industry and others to discuss the future efforts for collaboration in the field of kidney cancer research.
Learn more about KCRS and pre-register for KCRS24 now by visiting the website.
Kidney cancer is the ideal sandbox for these new approaches, and without a doubt the same approach can, should and will be suitable for other cancers.
Dr. Hans Hammers, UTSW
For this Community Spotlight feature, we spoke to Dr. Yousef Zakharia, a medical oncologist at the Holden Comprehensive Cancer Center and associate professor at the University of Iowa. Dr. Zakharia shares important information about finding the best care at...
This month, we asked Dr. Moshe Ornstein to share his insights in kidney cancer research and advocacy. He is a dedicated kidney cancer physician and researcher at the Cleveland Clinic. Dr. Ornstein completed his fellowship in Hematology & Oncology at the Cleveland...
Spring Advocacy : By the Numbers KidneyCAN is thrilled to announce the success of our Spring Advocacy Days event, which took place on March 13th in person in Washington, D.C., and on March 14th virtually. We are grateful for the 186 confirmed meetings with...